#France #ACROBiosystems #Villejuif #The HIVE

ACROBiosystems Expands in France

ACROBiosystems, a pioneering player in the biopharmaceutical sector, is making significant strides by opening a new office at The HIVE Innovation Center located in Villejuif, France. This initiative marks a pivotal step in the company's mission to integrate into the vibrant biotech ecosystem in the Paris-Saclay region, which is recognized for its exceptional scientific research and clinical excellence.

Founded in 2010, ACROBiosystems has become an indispensable partner for the global biopharma industry, boasting nearly 1,000 employees across its subsidiaries, research and development centers, and manufacturing sites in Europe, North America, and Asia. With a diverse clientele that includes top pharmaceutical and biotechnology firms, contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), and academic institutions, the company supports a comprehensive range of drug development processes. Its extensive portfolio encompasses recombinant proteins, antibodies, assay kits, and tailored scientific services of GMP quality.

The establishment of an office at The HIVE signifies ACROBiosystems' commitment to local engagement. By embedding itself within the Campus Grand Parc ecosystem, the company aims to foster connections and collaborations with various stakeholders involved in the development of next-generation cancer therapies. This ecosystem is home to biotech firms, hospitals, and institutes dedicated to translational research, providing an ideal environment for innovation and shared goals.

Since becoming a member of the Paris-Saclay Cancer Cluster (PSCC) in 2025, ACROBiosystems has already started building relationships within the life sciences community in the area. The new location at The HIVE is expected to further enhance their capabilities and partnerships, allowing them to leverage their global reach to benefit local initiatives.

The HIVE Innovation Center: A Hub for Collaboration

The HIVE Innovation Center aims to bring together life science companies of various sizes under one roof, facilitating informal daily interactions that can lead to innovative partnerships. For ACROBiosystems, the close proximity to an active scientific community is vital to their value proposition of being a reliable partner from discovery through to clinical application.

Mike Chen, Chairman and CEO of ACROBiosystems, emphasized the importance of this new location, stating, "France – particularly the Paris-Saclay region – sits at the intersection of world-class scientific research, clinical excellence, and a rapidly evolving biotech community. By expanding our presence at The HIVE, we position ourselves right where our partners live and work. We aim to be the reliable backbone of their scientific efforts, providing consistent quality, integrated innovation, and attentive service from discovery through to clinical application. Our purpose is not merely to open an office but to immerse ourselves in this ecosystem, to listen, collaborate, and grow with the teams that are working to advance tomorrow's therapies in oncology, immuno-oncology, advanced therapies, and beyond."

Sandrine Lo, Investment Asset Manager at Kadans Science Partner, expressed enthusiasm for ACROBiosystems' decision to expand at The HIVE, considering it a strong signal of the growing global attractiveness of the ecosystem.

About ACROBiosystems

The ACROBiosystems Group was founded with a mission to become a cornerstone of the global biopharma and health industry by providing innovative products and business models. It includes multiple subsidiaries, such as ACROBiosystems, bioSeedin, Condense Capital, and ACRODiagnostics. The company is dedicated to accelerating drug development across various therapeutic areas, including targeted therapies, immunotherapeutics, and their clinical applications, thereby contributing to global health.

About Kadans Science Partner

Kadans Science Partner is a leading European investment firm focused on developing ecosystems and real estate assets tied to knowledge-intensive industries. Their commitment to bringing people together to address global challenges is realized through investments in specialized properties that support scientific clusters. With a growing network across Europe, they continue to foster innovation in life sciences, health, agriculture, energy, and high-tech systems, making significant contributions to solving contemporary global challenges.

About the Paris-Saclay Cancer Cluster (PSCC)

The Paris-Saclay Cancer Cluster is a biomedical cluster of European significance that accelerates the pace of innovation in oncology, making research more anticipatory, precise, and effective. The cluster fosters collaboration within the cancer research community, providing promising European researchers with access to expertise, tools, and funding opportunities to advance their work in this critical area.